Comparability of JAK2 p.V617F allele burden in peripheral blood and that in bone marrow in patients with suspected myeloproliferative neoplasms: a single-center prospective study

Peripheral blood may be able to be used as an alternative to bone marrow for measuring JAK2 p.V617F allele burden in patients with suspected MPNs, according to data from a single-center prospective study of 54 patients. The same sensitivity and specificity was found in peripheral blood JAK2 p.V617F versus bone marrow (all P>0.05), and peripheral blood JAK2 p.V617F allele burden was comparable to that of bone marrow in a Chi-square test (Spearman Correlation =0.986; P=0.000).